Peritoneal Surface Disease Severity Score (PSDSS), AGO-score and TIAN model in patients with platinum-sensitive recurrent ovarian cancer treated by cytoreductive surgery plus HIPEC

• Published in: Clinical & experimental metastasis 2019-10, Vol.36 (5), p.433-439
• Main Authors: Gómez-Ruiz, Álvaro Jesús, González-Gil, Alida, Gil, José, Navarro-Barrios, Álvaro, Alconchel, Felipe, Gil, Elena, Martínez, Jerónimo, Nieto, Aníbal, Barceló, Francisco, Cascales-Campos, Pedro Antonio
• Format: Article
• Language: English
• Subjects: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biomedical and Life Sciences; Biomedicine; Cancer; Cancer Research; Chemotherapy; Combined Modality Therapy; Cytoreduction Surgical Procedures - methods; Decision making; Female; Follow-Up Studies; Gastric cancer; Hematology; Humans; Hyperthermia, Induced - methods; Middle Aged; Models, Statistical; Neoplasm Recurrence, Local - pathology; Neoplasm Recurrence, Local - therapy; Nomograms; Oncology; Ovarian cancer; Ovarian Neoplasms - pathology; Ovarian Neoplasms - therapy; Peritoneal Neoplasms - pathology; Peritoneal Neoplasms - therapy; Peritoneum; Platinum; Platinum - administration & dosage; Prognosis; Prospective Studies; Research Paper; Severity of Illness Index; Surgery; Surgical Oncology; Survival Rate; Taxoids - administration & dosage
• ISSN: 0262-0898; 1573-7276
• DOI: 10.1007/s10585-019-09982-1

In patients with platinum sensitive recurrent ovarian cancer selected for a secondary cytoreduction, the use of prognostic scores allows predicting the possibilities of a new complete cytoreduction. The aim of this work is to evaluate the usefulness of PSDSSov, the AGO-score and the TIAN-model as prognostic tools in these patients. Sixty four patients with recurrent platinum sensitive ovarian cancer treated by cytoreduction and HIPEC were analyzed between January 2008 and December 2016. Since 2012, the data needed to calculate the PSDSS, AGO-score and TIAN model were collected prospectively. Fifty patients (78%) received systemic chemotherapy before cytoreduction and HIPEC. In 57 patients (89%) a CC-0 was achieved. Patients with PSDSSov I–II and TIAN model of “low risk” had a DFS at 1 and 5 years of 71% and 57%, respectively, without reaching the median of DFS. PSDSSov is a useful prognostic tool and can be used in decision making in patients with peritoneal carcinomatosis due to recurrent platinum-sensitive ovarian cancer. Its combination with the Tian model makes it possible to identify patients with an especially favorable prognosis.